Defence Therapeutics Inc DTCFF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.03
- Day Range
- $0.98–0.98
- 52-Week Range
- $0.86–3.19
- Bid/Ask
- $0.83 / $0.91
- Market Cap
- $44.43 Mil
- Volume/Avg
- 750 / 748
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 5
Comparables
Valuation
|
Metric
|
DTCFF
|
NYKD
|
301080
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 34.86 |
Price/Book Value | — | 2.73 | 1.86 |
Price/Sales | — | 39.42 | 8.83 |
Price/Cash Flow | — | — | 49.04 |
Price/Earnings
DTCFF
NYKD
301080
Financial Strength
|
Metric
|
DTCFF
|
NYKD
|
301080
|
|---|---|---|---|
Quick Ratio | 0.14 | 8.43 | 13.32 |
Current Ratio | 0.18 | 8.43 | 14.50 |
Interest Coverage | — | — | 32.07 |
Quick Ratio
DTCFF
NYKD
301080
Profitability
|
Metric
|
DTCFF
|
NYKD
|
301080
|
|---|---|---|---|
Return on Assets (Normalized) | −530.04% | −18.26% | 4.53% |
Return on Equity (Normalized) | — | −23.64% | 4.86% |
Return on Invested Capital (Normalized) | −1,224.39% | −26.98% | 2.83% |
Return on Assets
DTCFF
NYKD
301080
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jzgjshdb | Fdrp | $586.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fssbwnhh | Yzqntqd | $115.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fwddztdf | Lqnsdv | $108.2 Bil | |
MRNA
| Moderna Inc | Vthtcxsw | Fkv | $54.0 Bil | |
BNTX
| BioNTech SE ADR | Ndzwqhmn | Glp | $21.8 Bil | |
ARGX
| argenx SE ADR | Yzbrrnh | Rxvs | $21.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Splgpjjm | Qwlbk | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vshlsctm | Rkgmnr | $14.6 Bil | |
INCY
| Incyte Corp | Zhmffwdq | Gswhgk | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ltxbntsnfx | Smprnrn | $12.3 Bil |